Field Marketing Director

Ransomware Group incransom hits: quantinuum.com. HookPhish team Target organization quantinuum.com quantinuum.com Technology Summary. In the latest cybersecurity news, quantinuum.com - an organization based in US - has fallen victim to a ransomware attack conducted by the group incransom. This data breach, discovered on Aug 1, 2026, 16:29 UTC, underscores the increasing need for proactive cybersecurity defenses as HookPhish continue through 2026. Incident report. | Target Organization | quantinuum.com | | Threat Group | incransom | | Summary | Quantinuum is a quantum computing company that develops advanced quantum computers, software, and cybersecurity solutions to solve complex scientific and industrial challenges. The company provides full-stack quantum technologies for areas such as materials science, drug discovery, encryption, artificial intelligence, and optimization, helping enterprises and researchers accelerate innovation through quantum computing. The leak dates back to pre-IPO. QUANTINUUM deliberately withheld this information from investors. The exact amount of stolen data will be revealed after publishing. | | Date of Breach | Aug 1, 2026, 16:00 UTC | | Discovery Date | Aug 1, 2026, 16:29 UTC | | Region | US | | Target Domain | quantinuum.com | | Business Sector | Technology | How to reduce your ransomware risk. Most ransomware intrusions start with a stolen password or a phishing email. A few proactive steps sharply cut your exposure: * realistic phishing tests - close the gap attackers exploit. * train staff to spot attacks - close the gap attackers exploit. Disclaimer. HookPhish does not engage in the exfiltration, downloading, taking, hosting, viewing, reposting, or disclosure of any stolen information. All breach data reported here is sourced from publicly available threat intelligence feeds for awareness purposes only.

Chemical and pharmaceutical giants Partnering with Quantum Technology companies for product development. Quantum Chemicals & Quantum Life Science July 29-August 4 Large chemical and pharmaceutical enterprises are actively partnering with quantum hardware and software providers to revolutionize product development. [1, 2] Because molecular simulation and biological optimizations naturally align with quantum mechanical properties, these industries are leading early commercial adoption. [1, 2, 3, 4, 5) Several key companies are engaging in strategic collaborations and partnerships to advance their technology and capitalize on the market's growth according to a Fortune Business Insights Report updated in June 2026. The report cites the June 2025, collaboration between IonQ and AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop a quantum-accelerated computational chemistry workflow with the potential to drive innovation in healthcare, life sciences, chemistry, and other fields. Corporate partnerships with Quantum Chemicals (materials, performance Chemicals & catalysts). Chemical conglomerates are partnering with quantum technology companies to discover advanced catalysts, optimize industrial reactions, and synthesize performance materials. [1, 2] German chemical and pharmaceutical giants like BASF and Merck KGaA are actively incorporating quantum computing by joining alliances like the Quantum Technology and Application Consortium (QUTAC) to fast-track industrial chemical simulations and materials science. [1, 2, 3] Key chemical consortia partnerships with quantum tech: * QUTAC: Founded by 10 German corporate leaders - including BASF and Merck - to translate quantum computing basics into market-ready chemical applications. [1] * SEEQC Collaboration: BASF and Merck KGaA joined as end-customer partners with SEEQC to leverage chip-based quantum platforms tailored for chemical reactions. [1] * HQS Quantum Simulations: Partnered with firms like Merck to utilize specialized software for quantum chemistry on near-term hardware. [1] * Boehringer Ingelheim: Partnered with Google Quantum AI to execute complex molecular simulations. They have successfully scaled up algorithmic research alongside PsiQuantum to drastically cut runtime requirements for modeling challenging, highly reactive chemical enzymes. [1, 2, 3] * Merck KGaA: Collaborating with Oxford University and the quantum hardware startup SEEQC under a UK-led consortium. They are specifically researching the co-development of a full-stack quantum platform targeted at chemical and molecular discovery. [1) * BMW Group: Partnered with Quantinuum to model chemical reactions inside EV batteries. They utilize quantum hardware to simulate new battery chemistries and optimize materials for superior energy density. [1, 2, 3, 4] * Nippon Steel: Partnering with Quantinuum to research structural carbon materials and industrial catalysts. Their focus is on predicting the chemical and thermal decay properties of molecular compounds. [1] Corporate partnerships/collaborations with key Life Science and quantum companies for genomics, drug discovery & mRNA. Pharma companies have been among the first to invest in quantum research and partnerships. Biopharma giants are forming major consortiums to simulate protein structures, optimize clinical trials, and engineer novel therapeutics. [1, 2] Merck, Roche, Pfizer, Johnson & Johnson, and others have not only filed patents in the quantum space but also formed collaborations with quantum technology companies. Key Life Science collaborations with quantum tech. Cleveland Clinic: Formed a landmark 10-year Discovery Accelerator partnership with IBM Quantum. The collaboration focuses on CAR T-cell therapy design, structural modeling of tumor microenvironments, and running advanced quantum algorithms for clinical trial site selection. [1, 2] Moderna: Partnering with IBM to utilize hybrid quantum-classical computing platforms. They are simulating high-dimensional mRNA secondary structures to accelerate the formulation of highly stable mRNA-based therapies. [, 2] GlaxoSmithKline: Utilizing D-Wave Quantum hybrid solvers and IBM hardware to tackle life-science optimization problems. Their teams target peptide sequence designs and automated fragment-linking for molecular discovery. [1, 2, 3] Amgen: Partnering with Quantinuum to execute quantum machine learning classifications for peptide binding. Additionally, they utilize IBM systems to analyze large-scale Electronic Health Records (EHR) to predict patient adherence patterns for chronic biological treatments. [, 3] AstraZeneca: Engaged in multi-partner initiatives with IBM Quantum utilizing next-generation processors like Heron and Condor. They are evaluating machine learning methods to handle clinical data imputation and optimize lead-compound selection. [1, 2] Biogen: Collaborating with 1QBit to utilize quantum-enhanced processing speeds for molecular structure comparison. Their research specifically focuses on accelerating discovery pipelines for complex neurological diseases like Alzheimer's and Parkinson's. QuPharma Initiative: The goal is to build application-specific quantum systems to model chemical and molecular behavior that standard supercomputers cannot handle efficiently. [1, 2] * Focus: Improving simulation tools for complex programs like cancer photodynamic therapies. [1] * Funding: Backed by a £6.85 million Innovate UK grant alongside consortium partners including Oxford Instruments and the University of Oxford. [1, 2]

Meet the Swiss start-up hoping to power the world's quantum revolution. Contributor. Jul 28, 2026, 03:00am EDT 0:00 / 4:02 Summary. The quantum computing race is heating up, with tech giants like Microsoft, Google, and IBM aiming for commercial quantum computers by 2029. Amidst this, Swiss startup ZuriQ has announced a $25.5 million seed funding round for its groundbreaking 2D quantum chip architecture. This innovative design promises significantly greater scalability and connectivity than traditional 1D approaches, allowing for thousands of qubits essential for real-world applications. ZuriQ has already successfully demonstrated a 3x3 array, the largest 2D array of its kind, validating its technology. This new funding will accelerate ZuriQ's research, development, and recruitment, positioning its unique architecture as a critical missing link for truly scalable quantum computing. The quantum computing race is hotting up. Microsoft has just announced the launch of its next-generation quantum chip and hopes to have a commercially viable quantum computer available by 2029. Google and IBM both say they're working to similar timescales. Elsewhere, the Nasdaq IPO of Quantinuum last month saw the company valued at $15 billion. The founders of Swiss start-up ZuriQ expect to play a big part in this revolution. The company, which is today announcing a $25.5 million seed funding round, has pioneered a new type of architecture for the construction of quantum computing chips. "Our approach offers greater scalability and connectivity for real-world applications," says Pavel Hrmo, the co-founder and CEO of ZuriQ. I first interviewed Hrmo and his colleagues in January 2025, just after the business had raised $4.2 million of funding to build a demonstration project that would showcase its technology. A little over 18 months later, Hrmo says that project has delivered exactly the results he was hoping for; and the company has expanded quickly to capitalise on this success, with headcount increasing from four people to 15 team members today. The critical problem ZuriQ is focused on is how to build chips containing thousands of "qubits" - the fundamental units of quantum information - so that they can function at the speed and power required. Traditionally, quantum developers have depended on an architecture in which ions are held in one-dimensional chains stitched together into larger grids. By contrast, ZuriQ has found a way to build two-dimensional structures. "What makes this approach powerful is geometry," says Professor Jonathan Home of ETH Zürich, a scientific adviser to ZuriQ. "Hold ions in a line and the count grows one at a time; hold them in two dimensions, and it grows with the area of the chip - on a standard chip, that is the difference between tens of ions and many thousands." MORE FOR YOU This architecture also supports usability, Home points out. "The ions can be moved freely in three dimensions, so they can be connected together far more flexibly, and that connectivity is what ultimately makes a quantum computer more capable." Hrmo points out that other quantum specialists are now trying to reverse-engineer one-dimensional approaches to capture these benefits. ZuriQ has an advantage, he argues, because it focused on two-dimensional architecture from the outset. "We spent longer in the lab, and that time allowed us to identify an alternative route that is inherently easier to scale." The demonstration project - a three-by-three array of nine individually controlled ions, the largest two-dimensional array of its kind demonstrated to date - has attracted significant attention. ZuriQ worked closely with manufacturing partner Infineon, Germany's largest semiconductor company, underlining the interest of established industry players in its technology. Hrmo and his co-founds, Tobias Sägesser and Shreyans Jain, are now determined to build on this progress. Today's fundraising will enable the company to significantly accelerate its recruitment, as well as to intensify research and development work. The $25.5 million round is led by Quantonation, with participation from Forward.one, Extantia, Firgun Ventures and all of the investors that took part in the company's previous raise. Christophe Jurczak, the founding partner of Quantonation, is convinced ZuriQ has a critical role to play in the future of quantum computing. "A common misconception is that the quantum race is already decided, but that is far from reality," he says. "ZuriQ is demonstrating that there remain significant and transformational physics breakthroughs still to be made in quantum architectures." Hrmo makes a similar point. "Other companies and academics have proven that quantum computers can be built, but we now have proof points for a brand-new architecture that could be the critical missing link," he argues. FORBES' FEATURED Video